Neuropsychiatric Symptoms of Epilepsy

18 The Role of Antiepileptic Drugs
353
31. Galeotti N, Bartolini A, Ghelardini C. Blockade of intracellular calcium release induces an
antidepressant-like effect in the mouse forced swimming test. Neuropharmacology.
2006;50(3):309–16.
32. Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renström E, Wietzorrek G, Berjukov S,
et al. Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular
function by L-type Ca 2+ channels. J Clin Invest. 2004;113(10):1430–9.
33. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat
neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280(2):107–10.
34. Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA. Amperometric measurement
of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role
of voltage-sensitive Ca 2+ α2δ-1 subunit. J Pharmacol Exp Ther. 2011;338(1):240–5.
35. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological,
and treatment perspectives. Lancet. 2012;379(9820):1045–55.
36. Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs.
J Psychopharmacol Oxf Engl. 1998;12(2):115–21.
37. Whitton PS, Oresković D, Jernej B, Bulat M. Effect of valproic acid on 5-hydroxytryptamine
turnover in mouse brain. J Pharm Pharmacol. 1985;37(3):199–200.
38. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Carbamazepine increases extracellular serotonin
concentration: lack of antagonism by tetrodotoxin or zero Ca 2+ . Eur J Pharmacol.
1997;328(2–3):153–62.
39. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin
elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine
and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett. 2005;390(1):48–53.
40. Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S, et al. Topiramate
and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin.
Epilepsy Res. 2009;84(2–3):172–86.
41. Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, et al. Biphasic effects of
zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34(2–3):
187–97.
42. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake
in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol.
1998;358(1):19–24.
43. Diehl DJ, Gershon S. The role of dopamine in mood disorders. Compr Psychiatry.
1992;33(2):115–20.
44. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect.
1993;91(2–3):75–109.
45. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment.
J Clin Psychiatry. 2006;67 Suppl 6:3–8.
46. Löscher W, Hönack D. Valproate and its major metabolite E-2-en-valproate induce different
effects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol.
1996;299(1–3):61–7.
47. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on
dopaminergic system. Epilepsy Res. 1995;22(3):193–205.
48. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic
conditions. Nat Med. 2004;10(7):685–92.
49. Grunze HCR. Anticonvulsants in bipolar disorder. J Ment Health Abingdon Engl.
2010;19(2):127–41.
50. Landolt H. Serial EEG investigations during psychotic episodes in epileptic patients and during
schizophrenic attacks. In: Lorenz de Haas AM, editor. Lectures on Epilepsia. Amsterdam:
Elsevier; 1958. p. 91–133.
51. Trimble MR, Schimtz B. Forced normalization and alternative psychoses of epilepsy.
Petersfield: Wrightson Biomedical Publishing Ltd.; 1998.
52. Gibbs FA. Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. J Nerv Ment
Dis. 1951;113(6):522–8.